JP2017518364A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518364A5
JP2017518364A5 JP2017512873A JP2017512873A JP2017518364A5 JP 2017518364 A5 JP2017518364 A5 JP 2017518364A5 JP 2017512873 A JP2017512873 A JP 2017512873A JP 2017512873 A JP2017512873 A JP 2017512873A JP 2017518364 A5 JP2017518364 A5 JP 2017518364A5
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutical composition
subject
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512873A
Other languages
English (en)
Japanese (ja)
Other versions
JP6836500B2 (ja
JP2017518364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/031117 external-priority patent/WO2015175957A1/en
Publication of JP2017518364A publication Critical patent/JP2017518364A/ja
Publication of JP2017518364A5 publication Critical patent/JP2017518364A5/ja
Application granted granted Critical
Publication of JP6836500B2 publication Critical patent/JP6836500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512873A 2014-05-16 2015-05-15 自己免疫状態および炎症状態を治療するための方法および組成物 Active JP6836500B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461994239P 2014-05-16 2014-05-16
US61/994,239 2014-05-16
US201462014504P 2014-06-19 2014-06-19
US62/014,504 2014-06-19
PCT/US2015/031117 WO2015175957A1 (en) 2014-05-16 2015-05-15 Methods and compositions for treating autoimmune and inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021017236A Division JP7222004B2 (ja) 2014-05-16 2021-02-05 自己免疫状態および炎症状態を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017518364A JP2017518364A (ja) 2017-07-06
JP2017518364A5 true JP2017518364A5 (enExample) 2018-06-21
JP6836500B2 JP6836500B2 (ja) 2021-03-03

Family

ID=54480787

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512873A Active JP6836500B2 (ja) 2014-05-16 2015-05-15 自己免疫状態および炎症状態を治療するための方法および組成物
JP2021017236A Active JP7222004B2 (ja) 2014-05-16 2021-02-05 自己免疫状態および炎症状態を治療するための方法および組成物
JP2023014370A Active JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021017236A Active JP7222004B2 (ja) 2014-05-16 2021-02-05 自己免疫状態および炎症状態を治療するための方法および組成物
JP2023014370A Active JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Country Status (8)

Country Link
US (2) US10993990B2 (enExample)
EP (1) EP3142691A4 (enExample)
JP (3) JP6836500B2 (enExample)
CN (1) CN106659774A (enExample)
AU (3) AU2015258875B2 (enExample)
CA (2) CA2949081C (enExample)
IL (2) IL300029A (enExample)
WO (1) WO2015175957A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA3064333A1 (en) * 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN109620952A (zh) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
JP7546924B2 (ja) 2019-03-01 2024-09-09 国立大学法人 筑波大学 アレルギー疾患を処置することに用いるための組成物
AU2020279240A1 (en) * 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CA3152181A1 (en) * 2019-08-23 2021-03-04 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
WO2022031929A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12rb1-binding molecules and methods of use
WO2022032042A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
KR102846963B1 (ko) 2020-08-05 2025-08-18 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
EP4192489A4 (en) 2020-08-05 2024-12-11 Synthekine, Inc. IL2RB-BINDING MOLECULES AND METHODS OF USE
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
MX2023001491A (es) 2020-08-05 2023-03-08 Synthekine Inc Moleculas de union a gp130 y metodos de uso.
JP7743500B2 (ja) 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド Ｉｌ１０受容体結合性分子および使用方法
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine, Inc. Compositions and methods related to il27 receptor binding
WO2022032005A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10rb binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032025A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr binding synthetic cytokines and methods of use
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
WO2022031942A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12rb2 binding molecules and methods of use
EP4216977A4 (en) * 2020-09-25 2025-04-16 The University of Chicago ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
FR3139339B1 (fr) * 2022-09-01 2025-10-24 Asfalia Biologics Conjugués peptidiques et leur utilisation pour promouvoir l’immunotolérance aux nucleases cas dans une thérapie génique par ingenierie du genome
WO2024233853A2 (en) * 2023-05-11 2024-11-14 Elixiron Immunotherapeutics (hong Kong) Limited A combination comprising lag-3 targeting moiety and interleukin-10
KR20260034078A (ko) * 2023-06-02 2026-03-10 신테카인, 인크. 융합된 il10 폴리펩티드
EP4771055A1 (en) * 2023-09-01 2026-07-08 The Regents Of The University Of Michigan Long-lived brain delivery of anti-inflammatory agents

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DE69434931T2 (de) 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
EP0859835A2 (en) 1995-10-17 1998-08-26 Genencor International, Inc. Enzymatic array and process of making same
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
FR2748479A1 (fr) 1996-05-10 1997-11-14 Pasteur Institut Polypeptide comportant un nouveau domaine cohesine de type ii, composition enzymatique en comportant et fragments d'adn codant pour ces polypeptides
US6046158A (en) 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
AR014891A1 (es) 1997-07-09 2001-04-11 Schering Corp Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
JP2000157282A (ja) 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
EP1165813A2 (en) 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Linear and circular expression elements
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
WO2000063151A1 (de) 1999-04-21 2000-10-26 Basf Aktiengesellschaft Gemisch von diestern der adipin- oder phthalsäure mit isomeren nonanolen
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
EP1418234A4 (en) 2000-03-02 2005-03-16 Abgenix Inc HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST OXIDIZED LDL RECEPTORS AND THEIR MEDICAL USE
US20060222633A1 (en) * 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
FR2816060A1 (fr) 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
WO2003018749A2 (en) 2001-08-22 2003-03-06 Shengfeng Li Compositions and methods for generating antigen-binding units
EP1441030A4 (en) 2001-10-11 2007-08-15 Katakura Ind Co Ltd PROCESS FOR CLEANING A RECOMBINANT FUSION PROTEIN AND METHOD FOR PRODUCING PROTEIN THEREWITH
WO2003036895A1 (en) 2001-10-25 2003-05-01 Renesas Technology Corp. Semiconductor integrated circuit for communication, modulating/demodulating device, and communication diagnosing method
CA2468878A1 (en) 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
AU2003213640A1 (en) 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US6738985B2 (en) 2002-05-14 2004-05-25 David S. Hahn Disposable sweatband liner
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2004236504A (ja) 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
KR101230724B1 (ko) * 2003-03-04 2013-02-07 알렉시온 파마슈티칼스, 인코포레이티드 항원 제공 세포의 내성을 유도함으로써 자가 면역 질환 치료 방법
US20050064509A1 (en) 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
WO2007041218A2 (en) 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
US8057798B2 (en) 2007-02-02 2011-11-15 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2132226B1 (en) 2007-02-23 2019-03-27 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
TWI423985B (zh) 2007-02-23 2014-01-21 貝勒研究協會 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用
FR2933816B1 (fr) * 2008-07-10 2015-08-21 Commissariat Energie Atomique Dispositif a coupleur selectif en longueur d'onde pour collection de la lumiere emise par une source laser.
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
CA2813494A1 (en) 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
EP2552483A4 (en) * 2010-04-01 2013-09-25 Immunomedics Inc USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS
CA2798616A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
AR083400A1 (es) 2010-10-13 2013-02-21 Baylor Res Inst Direccionamiento de los antigenos a las celulas dendriticas humanas a traves del receptor de asialoglicoproteinas dc para producir celulas t reguladoras con il-10
US20120121592A1 (en) * 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
EP2630493A4 (en) * 2010-10-22 2014-05-21 Univ Florida ANTIGEN-SPECIFIC TOLERANCE-INDUCING MICROPARTICLES AND USES THEREOF
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
US20120244155A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
US20120301465A1 (en) 2011-03-25 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods to immunize against hepatitis c virus
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2014210540A1 (en) * 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis

Similar Documents

Publication Publication Date Title
JP7507790B2 (ja) ＥｐＣＡＭ結合タンパク質および使用方法
JP7489316B2 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
TWI771361B (zh) 人程序性死亡受體pd-1的單株抗體及其片段
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
EP3892634A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
TW202005984A (zh) 結合pd-l1及cd137的抗體分子
TWI844524B (zh) 靶向edb之il-12組合物
US12428493B2 (en) Antibodies that bind PSMA and gamma-delta T cell receptors
CN107949571A (zh) 调控免疫反应的方法及抗体
CN110709421A (zh) 针对ox40和ctla-4的双特异性抗体
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
WO2018165895A1 (zh) Ctla4抗体、其药物组合物及其用途
US12612460B2 (en) Anti-PD-1 antibodies and fusion proteins
CN116801889A (zh) 包含具有多特异性抗体的离体武装t细胞的组合物和其用途
TW202221021A (zh) 改良之抗原結合受體
WO2013169693A1 (en) Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2022002009A1 (zh) 靶向ox40的抗体及其制备方法和应用
CN110343180B (zh) 抗ctla-4抗体及其应用
US20230257474A1 (en) Uveal melanoma treatment using sea-cd40
CA3259869A1 (en) DOSING REGIMEN FOR CD19-TARGETED CANCER IMMUNOTHERAPY
WO2021011912A1 (en) Combination of integrin-targeting knottin-fc fusion and anti-cd47 antibody for the treatment of cancer
TWI790193B (zh) 調控免疫反應之方法及抗體
JP2025514847A (ja) Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
WO2025154050A1 (en) Antibodies directed to slamf6